Scientific Letters: WWW - Elsevier.es/eimc
Scientific Letters: WWW - Elsevier.es/eimc
Scientific Letters: WWW - Elsevier.es/eimc
www.elsevier.es/eimc
Scientic letters
Multidrug-resistant tuberculous spondylitis
Espondilitis por tuberculosis multirresistente
To the Editor,
Multidrug-resistant tuberculosis (MDR-TB), dened as resistance to at least isoniazid and rifampin, is an important public
health problem.1 The skeletal system can be involved in 13% of all
tuberculosis cases2 ; however, there are very few reported cases of
skeletal MDR-TB. In addition to the challenges encountered when
treating pulmonary MDR-TB, osteoarticular MDR-TB poses additional difculties, due to the lack of evidence to guide treatment,
the unknown efcacy of second-line antituberculous drugs in the
bone, and the paucity of reports on this condition. We present a
patient with MDR-TB spondylitis with successful response to treatment.
A 32-year-old woman arrived in the emergency department
with a neck injury. One year before admission, she started having
posterior cervical pain and paresthesias in both hands. On admission, the radiography of the cervical spine showed destruction and
collapse of C7 vertebral body (Fig. 1), and a magnetic resonance
showed collapse of C7 and oedema of C6 , C7 , T1 , and T2 vertebral
bodies. She underwent surgical repair with implantation of C7 vertebral prosthesis for stabilisation. The bone biopsy of C7 showed
chronic osteomyelitis and granulomata with central necrosis. The
acid-fast stain was negative. The culture yielded Mycobacterium
tuberculosis, resistant to isoniazid, rifampicin and pyrazinamide,
and sensitive to ethambutol, streptomycin, amikacin, levooxacin,
ethionamide, cycloserine and para-amino salicylic acid.
She was transferred to our tuberculosis unit. On admission, the
physical examination was normal, the HIV serology was negative,
and the chest X-ray was normal.
She started directly observed treatment with ethambutol
1400 mg/day, ethionamide 750 mg/day, cycloserine 750 mg/day,
levooxacin 500 mg/day and intramuscular amikacin 1 g every
48 h. All drugs were administered for 18 months except amikacin,
which was administered for 3 months. There were no adverse
effects except polyarthralgias (which improved after substituting
moxioxacin for levooxacin in the third month). After 18 months
of therapy, she had no symptoms and a CT scan showed complete
resolution of the vertebral lesions. She declined to continue treatment and she did not return for follow-up. However, we contacted
her by telephone 28 months after the end of treatment and she told
us she had no symptoms of relapse.
Spondylitis due to MDR-TB is very infrequent: we have only
found 6 case reports and two small series3,4 in the literature, with
very little information on drug treatment. The optimal treatment
for osteoarticular MDR-TB is unknown. The treatment of nonresistant spinal TB is mainly medical, and surgery is reserved for
managing complications or failure of antimicrobial therapy.2,5,6
0213-005X/$ see front matter 2012 Elsevier Espaa, S.L. All rights reserved.
Document downloaded from http://http://www.elsevier.pt, day 28/05/2013. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
18 months since the patient did not wish to continue, she was
asymptomatic, and there was radiologic evidence of complete
recovery of the bone lesions. The 2011 update to the WHO guidelines has recently increased the recommended treatment time to a
minimum of 20 months.7
References
1. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: World Health Organization; 2008.
2. Tuli SM. General principles of osteoarticular tuberculosis. Clin Orthop Relat Res.
2002;398:119.
3. Pawar UM, Kundnani V, Agashe V, Nene A. Multidrug-resistant tuberculosis
of the spineis it the beginning of the end? A study of twenty-ve culture
proven multidrug-resistant tuberculosis spine patients. Spine (Phila Pa 1976).
2009;34:E80610.
4. Buyukbebeci O, Karakurum G, Daglar B, Maralcan G, Guner S, Gulec A. Tuberculous spondylitis: abscess drainage after failure of anti-tuberculous therapy. Acta
Orthop Belg. 2006;72:33741.
5. Jutte PC, Van Loenhout-Rooyackers JH. Routine surgery in addition to
chemotherapy for treating spinal tuberculosis. Cochrane Database Syst Rev.
2006:CD004532.
6. van Loenhout-Rooyackers JH, Verbeek AL, Jutte PC. Chemotherapeutic treatment
for spinal tuberculosis. Int J Tuberc Lung Dis. 2002;6:25965.
7. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva: World Health Organization; 2011.
425
8. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for
multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect
Dis. 2010;10:6219.
9. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of difcult multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2008;12:3456.
10. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300 mg dose
of linezolid for the treatment of intractable multidrug-resistant and extensively
drug-resistant tuberculosis. J Antimicrob Chemother. 2009;64:38891.
b,
author.
E-mail address: inessuarez@hotmail.com (I. Surez-Garca).
doi:10.1016/j.eimc.2012.02.018